Active substance
Etoposide
- SFDA 8
- US FDA 22
- Health Canada 3
- NHS prices 2
- WHO EML 1
- Safety 1
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ETOPOSID "EBEWE" 200MG VIAL | 20 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 78.35 | Generic · Prescription | EBEWE PHARMA | Valid |
| ETOPOSID "EBEWE" 20MG-ML VIAL | 20 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 42.60 | Generic · Prescription | EBEWE PHARMA | Valid |
| ETOPOSIDE-VENUS | 20 mg/ml | Solution for injection · Intravenous use | 1 Vial | SAR 40.20 | Generic · Prescription | VENUS REMEDIES LIMITED | Valid |
| ETOPOSID "EBEWE" 50 MG VIAL | 20 mg/ml | Concentrate for solution for infusion · Intravenous use | 1 Vial | SAR 28.30 | Generic · Prescription | EBEWE PHARMA | Withdrawn by MAH · Not Marketed |
| LASTET 100MG AMP FOR INFUSION | 100 mg | Solution · Intravenous use | 10 Ampoule | SAR 293.10 | Generic · Prescription | NIPPON KAYAKU | Invalid · Not Marketed |
| VEPESID 100MG CAPSULE | 100 mg | Capsule · Oral use | 10 Blister | SAR 500.05 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
| VEPESID 100MG\5ML AMP | 20 mg/ml | Injection · Intravenous use | 1 Vial | SAR 48.75 | Generic · Prescription | BRISTOL CARIBBEAN | Withdrawn by MAH · Not Marketed |
| VEPESID AMP 100MG-5ML FOR INFUSION | 20 mg/ml | Injection · Intravenous use | 10 Ampoule | SAR 788.55 | NCE · Prescription | BRISTOL-MYERS SQUIBB | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
ADULT ACUTE LYMPHOCYTIC LEUKEMIA (ALL); BONE SARCOMAS; BRAIN CANCERS; BURKITT`S LYMPHOMA; CASTLEMAN DISEASE; Cervical Cancer; DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL); FOLLICULAR LYMPHOMA; HODGKIN'S LYMPHOMA; MULTIPLE MYELOMA; Neuroblastoma; NEUROENDOCRINE TUMORS; NON-SMALL-CELL LUNG CARCINOMA (NSCLC); OVARIAN CANCER; PEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA (ALL); PEDIATRIC B-CELL LYMPHOMA; RETINOBLASTOMA; SMALL CELL LUNG CANCER (SCLC); SOFT TISSUE SARCOMA - RHABDOMYOSARCOMA; T-CELL LYMPHOMA; TESTICULAR CANCER; WILMS TUMOR
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| VEPESID | 50MG | capsule · oral | ONESOURCE SPECIALTY | Prescription | 30 Dec 1986 |
| ETOPOSIDE | 20MG/ML | injectable · injection | HIKMA PHARMS | Prescription | 17 Jul 1995 |
| ETOPOSIDE | 20MG/ML | injectable · injection | ACCORD HLTHCARE | Prescription | 14 Mar 1996 |
| ETOPOPHOS PRESERVATIVE FREE | EQ 100MG BASE/VIAL | injectable · injection | CHEPLAPHARM | Prescription | 17 May 1996 |
| ETOPOSIDE | 20MG/ML | injectable · injection | MEITHEAL | Prescription | 24 Jul 1996 |
| ETOPOSIDE | 20MG/ML | injectable · injection | FRESENIUS KABI USA | Prescription | 30 Sep 1998 |
| ETOPOSIDE | 50MG | capsule · oral | MYLAN | Prescription | 19 Sep 2001 |
| AVOPEF | 100MG/5ML (20MG/ML); 500MG/25ML (20MG/ML) | solution · intravenous | AVYXA HOLDINGS | Prescription | 13 Feb 2026 |
| VEPESID | 20MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | injectable · injection | CORDEN PHARMA | Discontinued | 10 Nov 1983 |
| VEPESID | 100MG | capsule · oral | ONESOURCE SPECIALTY | Discontinued | 30 Dec 1986 |
| ETOPOSIDE | 20MG/ML | injectable · injection | TEVA PHARMS USA | Discontinued | 10 Feb 1994 |
| TOPOSAR | 20MG/ML | injectable · injection | TEVA PARENTERAL | Discontinued | 27 Feb 1995 |
| ETOPOSIDE | 20MG/ML | injectable · injection | TEVA PARENTERAL | Discontinued | 29 Jun 1995 |
| ETOPOSIDE | 20MG/ML | injectable · injection | HOSPIRA | Discontinued | 30 Aug 1995 |
| ETOPOSIDE | 20MG/ML | injectable · injection | HOSPIRA | Discontinued | 30 Aug 1995 |
| ETOPOSIDE | 20MG/ML | injectable · injection | PHARMACHEMIE BV | Discontinued | 22 Feb 1996 |
| ETOPOSIDE | 20MG/ML | injectable · injection | PIERRE FABRE | Discontinued | 9 Jul 1997 |
| ETOPOSIDE | 20MG/ML | injectable · injection | WATSON LABS INC | Discontinued | 9 Jan 1998 |
| ETOPOPHOS PRESERVATIVE FREE | EQ 500MG BASE/VIAL; EQ 1GM BASE/VIAL | injectable · injection | BRISTOL MYERS SQUIBB | Discontinued | 27 Feb 1998 |
| ETOPOSIDE | 20MG/ML | injectable · injection | NATCO PHARMA USA | Discontinued | 31 Oct 2017 |
| ETOPOSIDE | 20MG/ML | injectable · injection | NATCO PHARMA USA | Discontinued | 20 Nov 2017 |
| ETOPOSIDE | 20MG/ML | injectable · injection | WATSON LABS | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ETOPOSIDE INJECTION | 02080036 | 20 MG / ML | SOLUTION · INTRAVENOUS | TEVA CANADA LIMITED |
| ETOPOSIDE INJECTION | 02552671 | 20 MG / ML | SOLUTION · INTRAVENOUS | HIKMA CANADA LIMITED |
| VEPESID | 00616192 | 50 MG | CAPSULE · ORAL | CHEPLAPHARM ARZNEIMITTEL GMBH |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| NHS Drug Tariff | Etoposide 100mg capsules | £174.46 | 10 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Etoposide 50mg capsules | £199.64 | 20 capsule | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 8.2.1. Cytotoxic medicines · complementary
Burkitt lymphoma including Burkitt leukaemia; Lymphoid leukaemia, not elsewhere classified; Myeloid leukaemia; Anaplastic large cell lymphoma, ALK-negative; Anaplastic large cell lymphoma, ALK-positive; Germ cell tumour of testis; Osteosarcoma of bone or articular cartilage of unspecified sites; Other specified malignant neoplasms of the ovary; Other specified malignant neoplasms of bronchus or lung; Hodgkin lymphoma; Malignant trophoblastic neoplasms of placenta; Retinoblastoma; Ewing sarcoma of bone or articular cartilage of unspecified sites; Malignant neoplasms of kidney, except renal pelvis
Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate) | Oral > Solid: 100 mg capsule; 50 mg capsule
Safety signals and safety-related labeling changes
- US FDA 2 Sep 2026 ETOPOPHOS PRESERVATIVE FREE — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.